Patent US4555503A successfully refreshed from Google Patents.
US4555503A
Expired / Lapsed
US
⏱️ 0.0 years remaining
N2 -(Substituted)carboxymethyl-N6 -(substituted)-lysyl-and αε-aminoalkyl)glycyl amino acid antihypertensive agents
Assignee: Merck and Co Inc
•
Filing: 1983-02-18
•
Granted: 1985-11-26
•
Expires: 2003-02-18
Abstract
Abstract Compounds of the formula: <IMAGE> wherein R2 is <IMAGE> wherein k is 2 to 5; R3 is hydrogen; loweralkyl and substituted loweralkyl where the substituents are carboxy, hydroxy, and amino; or aralkyl, substituted aralkyl, heteroaralkyl, and substituted heteroaralkyl where the aryl and heteroaryl substituents are carboxy, hydroxy, and amino; and C is COOR; CONH2; or CH2OH; and a pharmaceutically acceptable salt thereof; are inhibitors of angiotensin I converting enzyme useful as antihypertensive agents.
Inventors
- 👤 Arthur A. Patchett
- 👤 Mu T. Wu
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 17:31
CPC Classifications
C; C07; C07K; C07K5/00; C07K5/02; C07K5/022; C07K5/0222; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/80
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
774 words
A compound of the formula: ##STR43## wherein: R is hydrogen; loweralkyl; aralkyl; or, aryl; R 1 is hydrogen; alkyl of from 1 to 12 carbon atoms which include branched, cyclic and unsaturated alkyl groups; substituted loweralkyl wherein the substituent can be halo, hydroxy, carboxy, carboxamido, loweralkylthio, loweralkoxy, loweralkoxycarbonyl, loweraralkoxycarbonyl, amino, loweralkylamino, lowerdialkylamino, acylamino; substituted loweralkylamino, wherein the substituent can be halo, hydroxy, alkoxy or cyano; arloweralkylamino; cyclic amino; oxo, thio or ureido; aryloxy; arylthio; aralkyloxy; aralkylthio; benzofused cycloalkyl or bicycloalkyl of from 8-12 carbon atoms; aryl or heteroaryl which may be mono-, di- or trisubstituted by loweralkyl, hydroxy, loweralkoxy, halo, amino, acylamino, loweralkylthio or aminoloweralkyl; benzofused cycloalkyl or bicycloalkyl of from 8 to 12 carbon atoms; arloweralkyl; arloweralkenyl; heteroloweralkyl and heteroloweralkenyl in which the aryl or heteroaryl rings may be mono-, di- or tri-substituted by halo, loweralkyl, hydroxy, loweralkoxy, amino, loweralkylamino, diloweralkylamino, aminoloweralkyl, acylamino, carboxy; haloloweralkyl, nitro, cyano or sulfonamido; aralkyl or heteroaralkyl which include branched loweralkyl groups; substituted aralkyl or substituted heteroaralkyl which include branched loweralkyl groups wherein the loweralkyl groups can be substituted by amino, acylamino, or hydroxyl and the aryl and heteroaryl groups can be substituted by halo, dihalo, loweralkyl, hydroxy, loweralkoxy, aryloxy, aroyl, arylthio, amino, aminoloweralkyl, loweralkanoylamino, aroylamino, lowerdialkylamino, loweralkylamino, hydroxy, hydroxyloweralkyl, trihaloloweralkyl, nitro, cyano, or sulfonamido; any of the arloweralkyl or alkenyl and heteroloweralkyl or alkenyl groups described above in which the aryl or heteroaryl ring is partially or completely hydrogenated; substituted loweralkyl having the formula R A 1 (CH 2 ) n -Q-(CH 2 ) m wherein n is 0-2, m is 1-3, R A 1 is aryl or heteroaryl optionally substituted by amino, lowerdialkylamino, loweralkylamino, hydroxy, hydroxyloweralkyl, aminoloweralkyl, trihaloloweralkyl, cyano, nitro, sulfonamido, aroyl, loweralkyl, halo, dihalo, and loweralkoxy, and Q is O, S, SO, SO 2 , N--R B 1 , CONR C 1 , NR C 1 CO, CH═CH wherein R B 1 is hydrogen, loweralkyl, aryl, aralkyl, loweralkanoyl, or aroyl, and R C 1 is hydrogen, or loweralkyl; in the group: ##STR44## y is 0 to 4; A is (a) alkyl, including branched unsaturated and cyclic alkyl of 3 to 8 carbon atoms; (b) benzofused cycloalkyl or bicycloalkyl of 8 to 12 carbon atoms; (c) aryl or heteroaryl groups which may be mono-, di- or trisubstituted by loweralkyl; loweralkoxy, halo, amino, acylamino, hydroxy, acyl or acyloxy, and corresponding groups in which the aryl or heteroaryl groups are partially or completely hydrogenated; (d) loweralkyl including branched and unsaturated groups which may be substituted by aryl or heteroaryl groups and corresponding groups in which the aryl or heteroaryl rings are partially or completely hydrogenated; B is hydrogen or loweralkyl; or A and B may be joined, together with the carbon atoms to which they are attached to form a ring having the formulae: ##STR45## wherein X and Y taken together are ##STR46## R 5 and R 6 individually are hydrogen; loweralkyl; cycloalkyl; aryl; aralkyl; heteroaryl; loweralkyloxy; loweralkylthio; aryloxy; arylthio; arloweralkyloxy; arloweralkylthio; hydroxy; acyloxy; acylloweralkyl; halo; amino; mono- or disubstituted loweralkylamino; arloweralkylamino; heteroloweralkylamino acylamino in which the acyl group may be loweralkanoyl, aroyl, heteroaroyl or heteroloweralkanoyl; carbamoyl or N-substituted carbamoyloxy; including any of these groups containing an aromatic ring wherein said ring may be mono-, di- or trisubstituted by loweralkyl, loweralkoxy, loweralkylthio, halo, hydroxy, aryl, aryloxy, arylthio or aralkyl; any of the groups recited above containing an aryl or heteroaryl group in which these groups are partially or completely hydrogenated; R 7 is hydrogen, loweralkyl, cycloalkyl, aryl, substituted aryl wherein the substituent can be halo, hydroxy, alkoxy, amino or loweralkyl; or R 6 and R 7 taken together may be oxo or together with the carbon atoms to which they are attached form a 3 to 6 membered ring which may contain 0, 1 or 2 atoms of N, S or O; p and q are independently 0 to 3; ##STR47## wherein R 6 and R 7 are as defined above and r is 0, 1 or 2; ##STR48## wherein: W is absent; --CH 2 --; ##STR49## N; or S; Z is --(CH 2 ) t , wherein t is 0 to 2, provided that m may not be O when W is absent; --O--; --N--, or --S--. R 8 is hydrogen; loweralkyl; loweralkoxy; hydroxy; halo; loweralkylthio; amino; acylamino; or cyano; s is 1 to 3; R 2 is ##STR50## where k is 2 to 5; R 3 is hydrogen; loweralkyl and substituted loweralkyl where the substituents are carboxy, hydroxy, and amino; or aralkyl, substituted aralkyl, heteroaralkyl, and substituted heteroaralkyl where the aryl and heteroaryl substituents are carboxy, hydroxy, and amino; and D is COOR; CONH 2 ; or CH 2 OH; and a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
774 words
A compound of the formula: ##STR43## wherein: R is hydrogen; loweralkyl; aralkyl; or, aryl; R 1 is hydrogen; alkyl of from 1 to 12 carbon atoms which include branched, cyclic and unsaturated alkyl groups; substituted loweralkyl wherein the substituent can be halo, hydroxy, carboxy, carboxamido, loweralkylthio, loweralkoxy, loweralkoxycarbonyl, loweraralkoxycarbonyl, amino, loweralkylamino, lowerdialkylamino, acylamino; substituted loweralkylamino, wherein the substituent can be halo, hydroxy, alkoxy or cyano; arloweralkylamino; cyclic amino; oxo, thio or ureido; aryloxy; arylthio; aralkyloxy; aralkylthio; benzofused cycloalkyl or bicycloalkyl of from 8-12 carbon atoms; aryl or heteroaryl which may be mono-, di- or trisubstituted by loweralkyl, hydroxy, loweralkoxy, halo, amino, acylamino, loweralkylthio or aminoloweralkyl; benzofused cycloalkyl or bicycloalkyl of from 8 to 12 carbon atoms; arloweralkyl; arloweralkenyl; heteroloweralkyl and heteroloweralkenyl in which the aryl or heteroaryl rings may be mono-, di- or tri-substituted by halo, loweralkyl, hydroxy, loweralkoxy, amino, loweralkylamino, diloweralkylamino, aminoloweralkyl, acylamino, carboxy; haloloweralkyl, nitro, cyano or sulfonamido; aralkyl or heteroaralkyl which include branched loweralkyl groups; substituted aralkyl or substituted heteroaralkyl which include branched loweralkyl groups wherein the loweralkyl groups can be substituted by amino, acylamino, or hydroxyl and the aryl and heteroaryl groups can be substituted by halo, dihalo, loweralkyl, hydroxy, loweralkoxy, aryloxy, aroyl, arylthio, amino, aminoloweralkyl, loweralkanoylamino, aroylamino, lowerdialkylamino, loweralkylamino, hydroxy, hydroxyloweralkyl, trihaloloweralkyl, nitro, cyano, or sulfonamido; any of the arloweralkyl or alkenyl and heteroloweralkyl or alkenyl groups described above in which the aryl or heteroaryl ring is partially or completely hydrogenated; substituted loweralkyl having the formula R A 1 (CH 2 ) n -Q-(CH 2 ) m wherein n is 0-2, m is 1-3, R A 1 is aryl or heteroaryl optionally substituted by amino, lowerdialkylamino, loweralkylamino, hydroxy, hydroxyloweralkyl, aminoloweralkyl, trihaloloweralkyl, cyano, nitro, sulfonamido, aroyl, loweralkyl, halo, dihalo, and loweralkoxy, and Q is O, S, SO, SO 2 , N--R B 1 , CONR C 1 , NR C 1 CO, CH═CH wherein R B 1 is hydrogen, loweralkyl, aryl, aralkyl, loweralkanoyl, or aroyl, and R C 1 is hydrogen, or loweralkyl; in the group: ##STR44## y is 0 to 4; A is (a) alkyl, including branched unsaturated and cyclic alkyl of 3 to 8 carbon atoms; (b) benzofused cycloalkyl or bicycloalkyl of 8 to 12 carbon atoms; (c) aryl or heteroaryl groups which may be mono-, di- or trisubstituted by loweralkyl; loweralkoxy, halo, amino, acylamino, hydroxy, acyl or acyloxy, and corresponding groups in which the aryl or heteroaryl groups are partially or completely hydrogenated; (d) loweralkyl including branched and unsaturated groups which may be substituted by aryl or heteroaryl groups and corresponding groups in which the aryl or heteroaryl rings are partially or completely hydrogenated; B is hydrogen or loweralkyl; or A and B may be joined, together with the carbon atoms to which they are attached to form a ring having the formulae: ##STR45## wherein X and Y taken together are ##STR46## R 5 and R 6 individually are hydrogen; loweralkyl; cycloalkyl; aryl; aralkyl; heteroaryl; loweralkyloxy; loweralkylthio; aryloxy; arylthio; arloweralkyloxy; arloweralkylthio; hydroxy; acyloxy; acylloweralkyl; halo; amino; mono- or disubstituted loweralkylamino; arloweralkylamino; heteroloweralkylamino acylamino in which the acyl group may be loweralkanoyl, aroyl, heteroaroyl or heteroloweralkanoyl; carbamoyl or N-substituted carbamoyloxy; including any of these groups containing an aromatic ring wherein said ring may be mono-, di- or trisubstituted by loweralkyl, loweralkoxy, loweralkylthio, halo, hydroxy, aryl, aryloxy, arylthio or aralkyl; any of the groups recited above containing an aryl or heteroaryl group in which these groups are partially or completely hydrogenated; R 7 is hydrogen, loweralkyl, cycloalkyl, aryl, substituted aryl wherein the substituent can be halo, hydroxy, alkoxy, amino or loweralkyl; or R 6 and R 7 taken together may be oxo or together with the carbon atoms to which they are attached form a 3 to 6 membered ring which may contain 0, 1 or 2 atoms of N, S or O; p and q are independently 0 to 3; ##STR47## wherein R 6 and R 7 are as defined above and r is 0, 1 or 2; ##STR48## wherein: W is absent; --CH 2 --; ##STR49## N; or S; Z is --(CH 2 ) t , wherein t is 0 to 2, provided that m may not be O when W is absent; --O--; --N--, or --S--. R 8 is hydrogen; loweralkyl; loweralkoxy; hydroxy; halo; loweralkylthio; amino; acylamino; or cyano; s is 1 to 3; R 2 is ##STR50## where k is 2 to 5; R 3 is hydrogen; loweralkyl and substituted loweralkyl where the substituents are carboxy, hydroxy, and amino; or aralkyl, substituted aralkyl, heteroaralkyl, and substituted heteroaralkyl where the aryl and heteroaryl substituents are carboxy, hydroxy, and amino; and D is COOR; CONH 2 ; or CH 2 OH; and a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
12 words
A compound of claim 1 which is: N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carboxymethyl-L-lysyl]-L-proline.
Claim 4
Dependent Claim
12 words
A compound of claim 1 which is: N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carbamoylmethyl-L-lysyl]-L-proline.
Claim 5
Dependent Claim
12 words
A compound of claim 1 which is: N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-L-proline.
Claim 6
Dependent Claim
12 words
A compound of claim 1 which is: N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 carboxymethyl-L-lysyl]-N-indanylglycine.
Claim 7
Dependent Claim
12 words
A compound of claim 1 which is: N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carbamoylmethyl-L-lysyl]-N-indanylglycine.
Claim 8
Dependent Claim
12 words
A compound of claim 1 which is: N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-N-indanylglycine.
Claim 9
Dependent Claim
14 words
A compound of claim 1 which is: N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carboxymethyl-L-lysyl] -1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
Claim 10
Dependent Claim
13 words
A compound of claim 1 which is: N-[N 2 -(1(S)carboxy-3-phenylpropyl)-N 6 -carbamoylmethyl-L-lysyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
Claim 11
Dependent Claim
13 words
A compound of claim 1 which is: N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
Claim 12
Dependent Claim
13 words
A compound of claim 1 which is: N-[N 2 -(1(S)carboxy-3-phenylpropyl)-N 6 -carboxymethyl-L-lysyl]-perhydroindole-2-carboxylic acid.
Claim 13
Dependent Claim
13 words
A compound of claim 1 which is: N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carbamoylmethyl-L-lysyl]-perhydroindole-2-carboxylic acid.
Claim 14
Dependent Claim
13 words
A compound of claim 1 which is: N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-perhydroindole-2-carboxylic acid.
Claim 15
Dependent Claim
23 words
A pharmaceutical composition useful in treating hypertension comprising a pharmaceutically acceptable carrier; and, an antihypertensively effective amount of a compound of claim 1.
Claim 16
Dependent Claim
84 words
A composition of claim 14 wherein said compound is a member selected from the group consisting essentially of: N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carboxymethyl-L-lysyl]-L-proline; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carbamoylmethyl-L-lysyl]-L-proline; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-L-proline; N-[N 2 -(2(S)-carboxy-3-phenylpropyl)-N 6 -carboxymethyl-L-lysyl]-N-indanylglycine; N-[N 2 -(1(S)-carboxy-3-phenylptopyl)-N 6 -carbamoylmethyl-L-lysyl]-N-indanylglycine; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-N-indanylglycine; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carboxymethyl-L-lysyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; N-[N 2 -(1(S)-carboxy-3-phenylptopyl)-N 6 -carbamoylmethyl-L-lysyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carboxymethyl-L-lysyl]-perhydroindole-2-carboxylic acid; N-[N 2 -(1(S)-carboxy-3-phenylpropyl-N 6 -carbamoylmethyl-L-lysyl]-perhydroindole-2-carboxylic acid; and, N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-perhydroindole-2-carboxylic acid.
Claim 17
Dependent Claim
25 words
A method of treating hypertension comprising administering to a patient in need of such treatment an antihypertensively effective amount of a compound of claim 1.
Claim 18
Dependent Claim
85 words
The method of claim 16 wherein said compound is a member selected from the group consisting essentially of: N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carboxymethyl-L-lysyl]-L-proline; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carbamoylmethyl-L-lysyl]-L-proline; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-L-proline; N-[N 2 -(2(S)-carboxy-3-phenylpropyl)-N 6 -carboxymethyl-L-lysyl]-N-indanylglycine; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carbamoylmethyl-L-lysyl]-N-indanylglycine; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-N-indanylglycine; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carboxymethyl-L-lysyl]-1,2,3,4-tetrahydroisoquinoline -3-carboxylic acid; N-[N 2 -(1(S)-carboxy-3-phenylpropyl-N 6 -carbamoylmethyl-L-lysyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; N-[N 2 -(1(S)-carboxy-3-phenylpropyl-N 6 -carbamoylmethyl-L-lysyl]-perhydroindole-2-carboxylic acid; and, N-[N 2 -(1(S)-carboxy-3-phenylpropyl-N 6 -hydroxyethyl-L-lysyl]-perhydroindole-2-carboxylic acid;
Claim 19
Dependent Claim
111 words
A pharmaceutical composition useful in the treatment of hypertension which comprises a pharmaceutically acceptable carrier; an antihypertensively effective amount of a compound of claim 1; and, an antihypertensive and/or diuretic compound selected from the group consisting of acetazolamide, amiloride, aminophylline, atenolol, benzofluoromethiazide, benzthiazide, bumetanide, chlorothalidone, chlorothiazide, clonidine, cryptenamine acetates and cryptenamine tannates, cyclothiazide, deserpidine, diazoxide, diltiazem, (S)-1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-[[4-(2-thienyl)-1H-imidazol-2-yl]phenoxy]-2-propanol, ethacrynic acid, fluoromethiazide, furosemide, guanethidene sulfate, hydralazine hydrochloride, hydrochlorothiazaide, hydrofluoromethiazide, (+)-4-[3-[-[2-(1-hydroxycyclohexyl)ethyl]-4-oxo-2-thiazolidinyl]propyl]-benzoic acid, indacrinone and variable ratios of its enantiomers, merethoxylline procaine, methylclothiazide, methyldopa, methyldopate hydrochloride, metolazone, metoprolol tartate, minoxidil, naldolol, nifedipine, pargyline hydrochloride, pindolol, polythiazide, prazosin, propranolol, quinethazone, rauwolfia serpentina, rescinnamine, reserpine, sodium ethacrynate, sodium nitroprusside, spironolactone, ticrynafen, timolol, triamterene, trichlormethiazide, trimethophan camsylate, verapamil.
Claim 20
Dependent Claim
88 words
The composition of claim 18 wherein said compound of claim 1 is a member selected from the group consisting essentially of: N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carboxymethyl-L-lysyl]-L-proline; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carbamoylmethyl-L-lysyl]-L-proline; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-L-proline; N-[N 2 -(2(S)-carboxy-3-phenylpropyl)-N 6 -carboxymethyl-L-lysyl] -N-indanylglycine; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carbamoylmethyl-L-lysyl]-N-indanylglycine; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-N-indanylglycine; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carboxymethyl-L-lysyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carbamoylmethyl-L-lysyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carboxymethyl-L-lysyl]-perhydroindole-2-carboxylic acid; N-[N 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -carbamoylmethyl-L-lysyl]-perhydroindole-2-carboxylic acid; and, N-[N.sup. 2 -(1(S)-carboxy-3-phenylpropyl)-N 6 -hydroxyethyl-L-lysyl]-perhydroindole-2-carboxylic acid.
Claim 21
Dependent Claim
32 words
A pharmaceutical composition useful in the treatment of hypertension which comprises a pharmaceutically acceptable carrier; an antihypertensively effective amount of a compound of claim 19; and a therapeutically effective amount of hydrochlorothiazide.
Claim 22
Dependent Claim
32 words
A pharmaceutical composition useful in the treatment of hypertension which comprises a pharmaceutically acceptable carrier; an antihypertensively effective amount of a compound of claim 19; and a therapeutically effective amount of timolol.
Claim 23
Dependent Claim
35 words
A pharmaceutical composition useful in the treatment of hypertension which comprises a pharmaceutically acceptable carrier; an anti-hypertensively effective amount of a compound of claim 19; and a therapeutically effective amount of manipulated indacrinone enantiomer ratio.
References Cited (Backward Citations)
US4113715A
Cited
US4129571A
Cited
US4154960A
Cited
EP0012401A1
Cited
EP0050800A1
Cited
GB2095682A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-11-25 | 1989-05-27 | 1989-11-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-11-25 | 1993-05-27 | 1993-11-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-11-25 | 1997-05-27 | 1997-11-26 | $7700.00 | Window Closed / Lapsed |